secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2024-12-23T23:59:59+00:00
Accession:  0001104659-24-131037
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio launches Phase 2 TibuSURE study of tibulizumab in systemic sclerosis
-----------------------------------------------------------------------------

- TibuSURE is a global Phase 2 double-blind, placebo-controlled trial in ~80 adults with early diffuse cutaneous systemic sclerosis.
- First clinical trial to target both BAFF and IL-17 pathways in SSC, using dual-antagonist antibody tibulizumab.
- Primary endpoint is modified Rodnan Skin Score; key endpoints include lung function (qHRCT, FVC) and physical function (HAQ-DI, rCRISS).
- Study includes 24-week efficacy period followed by a 28-week open-label extension.
- First clinical site has been initiated; results expected to inform further development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465924131037/0001104659-24-131037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465924131037/tm2431378d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-131037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer